Plain-English translation of NCT03725202 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Vasculitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested whether a medication called could help people with giant cell arteritis—an inflammatory condition that affects blood vessels and causes pain and vision problems. Participants received either the medication or a placebo while gradually reducing their steroid doses. The study examined whether the medication helped people achieve and maintain remission (when symptoms go away or become very controlled).
Giant cell arteritis typically requires long-term steroid treatment, which can cause serious side effects over time. This trial investigated whether this medication could allow people to reduce their steroid doses faster while still controlling their disease.
Participants took a daily tablet (either the medication or placebo) and followed a structured plan to gradually reduce their steroid dose over 6 to 12 months during the first phase of the trial. Those who achieved remission continued into a second phase where they either continued or stopped taking the medication to see how well remission was maintained. Throughout the study, participants had regular visits to monitor their symptoms, disease activity, and side effects.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States